Abstract | BACKGROUND: AIM: To assess the feasibility of a CGT in healthy subjects and patients with decreased enterocyte mass. METHODS: RESULTS: Following the oral bolus of alanine- glutamine, plasma citrulline concentrations showed a time dependent rise in healthy subjects of 44 +/- 13% (38-55 micromol/L, P < 0.0001). The slope from baseline plasma citrulline to peak concentrations was 0.22 +/- 0.08, 0.13 +/- 0.04 and 0.09 +/- 0.04 micromol/L/min in healthy subjects, patients with coeliac disease (CeD) and refractory CeD, respectively (healthy subjects vs. CeD P < 0.05, healthy subjects vs. refractory CeD P < 0.001). In patients with SBS, the CGT was able to distinguish between non-adapted and adapted SBS by means of the incremental area under the CGT curve till 90 min (iAUC T90). The iAUC T90 was 447 +/- 179 and 1039 +/- 178 micromol/L/min in non-adapted and adapted SBS, respectively (P = 0.04). CONCLUSION: An oral bolus of alanine- glutamine induces a time-dependent rise in plasma citrulline concentration to an extent dependent on the existence of villous atrophy or enterocyte hyperplasia in CeD, and adapted SBS, respectively.
|
Authors | J H C Peters, N J Wierdsma, T Teerlink, P A M van Leeuwen, C J J Mulder, A A van Bodegraven |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 27
Issue 12
Pg. 1300-10
(Jun 2008)
ISSN: 1365-2036 [Electronic] England |
PMID | 18331613
(Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adult
- Biomarkers
(metabolism)
- Calorimetry
- Celiac Disease
(metabolism, therapy)
- Citrulline
(administration & dosage, metabolism)
- Cross-Sectional Studies
- Enterocytes
(metabolism)
- Female
- Humans
- Intestinal Absorption
(physiology)
- Male
- Treatment Outcome
|